Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Clinical trial NCT05001412 · UNKNOWN
Trial details
- NCT number
- NCT05001412
- Sponsor
- Zhou Chengzhi
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-27
- Primary completion
- 2023-01-25
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.